Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial

被引:76
作者
Koukourakis, MI
Kourousis, C
Kamilaki, M
Koukouraki, S
Giatromanolaki, A
Kakolyris, S
Kotsakis, A
Androulakis, N
Bahlitzanakis, N
Georgoulias, V
机构
[1] Univ Hosp Heraklion, Dept Radiat Oncol, Heraklion 71110, Crete, Greece
[2] Univ Hosp Heraklion, Dept Med Oncol, Heraklion 71110, Crete, Greece
[3] Venizelion Gen Hosp, Dept Lung Dis, Heraklion 71110, Crete, Greece
关键词
docetaxel; radiotherapy; lung cancer;
D O I
10.1016/S0959-8049(97)10101-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this phase I/II study, we investigated the radiosensitising effects of docetaxel in non-small cell lung cancer (NSCLC). 30 patients with stage IIIb (18 patients) and IV (12 patients) NSCLC were treated with 64 Gy of accelerated chest radiotherapy (5-week schedule using a concomitant boost technique) and docetaxel on a weekly basis. The docetaxel starting dose level was 20 mg/m(2)/week and was escalated by 10 mg/m(2) increments in cohorts of 10 patients. Dose-limiting toxicity (grade 3 asthenia) was observed in 6 of 10 patients treated at the 40 mg/m(2)/week dose level, enforcing a 50% dose reduction in 4 patients. Grade 3 neutropenia was observed in 5 of 30 patients (17%), 3 of which were treated at the high dose level. Peripheral neuropathy occurred in 3 (10%) patients. A significant decrease in the absolute lymphocyte count was observed in all patients; the nadir was reached on day 28 (mean +/- standard deviation (S.D.) = 539 +/- 363/ml) compared with pretreatment values (mean +/- S.D. = 1842 +/- 863/ ml; P = 0.002). 6 out of 30 patients (20%) experienced grade 3 oesophagitis, resulting in a 1-2 week delay in overall treatment time. Complete response of the primary tumour was observed in 8 (27%) patients assessed 2 months after treatment. 4 of these patients had disease resistant to previous docetaxel-containing chemotherapy. A partial response occurred in 15 of 30 patients (50%) for an overall response rate of 77% (95% confidence interval (CI) 60-92%). Radiosensitisation with docetaxel is feasible and the recommended dose for further phase II studies is 30 mg/m(2)/week. Further phase II studies are required to confirm the remarkably high response rate observed in the present trial. (C) 1998 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:838 / 844
页数:7
相关论文
共 28 条
[1]  
Androulakis N, 1996, 2ND INTERNATIONAL CONGRESS ON LUNG CANCER, P661
[2]  
[Anonymous], 1979, HDB REP RES CANC TRE
[3]  
BISHOP JF, 1994, SEMIN ONCOL, V21, P91
[4]  
BRODIN O, 1996, EUR J CANCER, V32, P1892
[5]   DOCETAXEL (TAXOTERE(TM)) IS ACTIVE IN NON-SMALL-CELL LUNG-CANCER - A PHASE-II TRIAL OF THE EORTC EARLY CLINICAL-TRIALS GROUP (ECTG) [J].
CERNY, T ;
KAPLAN, S ;
PAVLIDIS, N ;
SCHOFFSKI, P ;
EPELBAUM, R ;
VANMEERBEEK, J ;
WANDERS, J ;
FRANKLIN, HR ;
KAYE, S .
BRITISH JOURNAL OF CANCER, 1994, 70 (02) :384-387
[6]  
CHAFFEY JT, 1971, CANCER RES, V31, P1513
[7]  
CHOY H, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P500
[8]   A RANDOMIZED TRIAL OF INDUCTION CHEMOTHERAPY PLUS HIGH-DOSE RADIATION VERSUS RADIATION ALONE IN STAGE-III NON-SMALL-CELL LUNG-CANCER [J].
DILLMAN, RO ;
SEAGREN, SL ;
PROPERT, KJ ;
GUERRA, J ;
EATON, WL ;
PERRY, MC ;
CAREY, RW ;
FREI, EF ;
GREEN, MR .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (14) :940-945
[9]   PHASE-II STUDY OF DOCETAXEL FOR RECURRENT OR METASTATIC NON-SMALL-CELL LUNG-CANCER [J].
FOSSELLA, FV ;
LEE, JS ;
MURPHY, WK ;
LIPPMAN, SM ;
CALAYAG, M ;
PANG, A ;
CHASEN, M ;
SHIN, DM ;
GLISSON, B ;
BENNER, S ;
HUBER, M ;
PEREZSOLER, R ;
HONG, WK ;
RABER, M .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (06) :1238-1244
[10]   PHASE-II TRIAL OF DOCETAXEL IN PATIENTS WITH PLATINUM-REFRACTORY ADVANCED OVARIAN-CANCER [J].
FRANCIS, P ;
SCHNEIDER, J ;
HANN, L ;
BALMACEDA, C ;
BARAKAT, R ;
PHILLIPS, M ;
HAKES, T .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (11) :2301-2308